We are live on ! Find out more
NTUS

Natus Medical Inc

Delisted

NTUS was delisted on the 20th of July, 2022.

217 hedge funds and large institutions have $1.16B invested in Natus Medical Inc in 2017 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 86 increasing their positions, 65 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

32% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 65

18% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 28

2% more funds holding

Funds holding: 212217 (+5)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

5% less capital invested

Capital invested by funds: $1.22B → $1.16B (-$57.7M)

19% less call options, than puts

Call options by funds: $2.72M | Put options by funds: $3.36M

Holders
217
Holders Change
+5
Holders Change %
+2.36%
% of All Funds
5.41%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
33
Increased
86
Reduced
65
Closed
28
Calls
$2.72M
Puts
$3.36M
Net Calls
-$639K
Net Calls Change
-$316K
Name Holding Trade Value Shares
Change
Change in
Stake
Point72 Asset Management
26
Point72 Asset Management
Connecticut
$9.57M +$9.27M +256,500 New
Principal Financial Group
27
Principal Financial Group
Iowa
$9.42M +$67.9K +1,879 +0.7%
Ameriprise
28
Ameriprise
Minnesota
$9.33M -$8.38M -231,921 -48%
LSC
29
Lyon Street Capital
California
$8.61M -$18.9M -524,377 -69%
Prudential Financial
30
Prudential Financial
New Jersey
$8.39M +$5.03M +139,130 +162%
TCIM
31
TIAA CREF Investment Management
New York
$8.14M +$16.5K +458 +0.2%
BCM
32
Beddow Capital Management
Wyoming
$7.88M +$700K +19,385 +10%
Citadel Advisors
33
Citadel Advisors
Florida
$7.87M +$572K +15,821 +8%
Charles Schwab
34
Charles Schwab
California
$6.19M -$1.06M -29,237 -15%
UBS Group
35
UBS Group
Switzerland
$6.06M +$3.16M +87,454 +117%
Deutsche Bank
36
Deutsche Bank
Germany
$5.98M +$4.23M +116,995 +269%
MWNA
37
Marshall Wace North America
New York
$5.83M +$5.69M +157,609 New
Morgan Stanley
38
Morgan Stanley
New York
$5.53M +$2.36M +65,227 +79%
Bank of America
39
Bank of America
North Carolina
$5.48M -$2.22M -61,425 -29%
ACH
40
ArrowMark Colorado Holdings
Colorado
$5.18M +$5.02M +139,005 New
MFAM
41
Motley Fool Asset Management
Virginia
$5.11M
Renaissance Technologies
42
Renaissance Technologies
New York
$4.74M -$807K -22,332 -15%
HIMCH
43
Hartford Investment Management Co (HIMCO)
Connecticut
$4.28M +$4.14M +114,657 New
BC
44
Broadfin Capital
New York
$4.16M +$4.03M +111,500 New
QI
45
QS Investors
New York
$3.93M -$24.7K -685 -0.6%
SO
46
STRS Ohio
Ohio
$3.92M +$3.48M +96,300 +1,107%
Invesco
47
Invesco
Georgia
$3.8M +$294K +8,134 +9%
USAA
48
United Services Automobile Association
Texas
$3.74M +$29.3K +810 +0.8%
TCM
49
Tygh Capital Management
Oregon
$3.63M +$3.52M +97,348 New
Goldman Sachs
50
Goldman Sachs
New York
$3.43M +$1.16M +31,994 +53%

NTUS Hedge Fund Activity: Q2 2017 in Review

217 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Natus Medical Inc (NTUS) for Q2 2017, worth a combined $1.16B — down 4.7% from $1.22B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new NTUS positions and 28 closed out — a net gain of 5 holders — while 86 added to existing stakes and 65 trimmed.

The largest buyer was Confluence Investment Management, adding an estimated $13.1M. The largest seller was Lyon Street Capital, cutting an estimated $18.9M.

  • 217 institutional investors held Natus Medical Inc (NTUS) as of Q2 2017, up from 212 in Q1 2017.
  • Funds reported $1.16B of Natus Medical Inc stock for Q2 2017, down 4.7% quarter-over-quarter.
  • 33 funds opened new Natus Medical Inc positions in Q2 2017 and 28 closed out, a net change of +5 holders.
  • The largest Natus Medical Inc buyer in Q2 2017 was Confluence Investment Management, an estimated $13.1M added.
  • The largest Natus Medical Inc seller in Q2 2017 was Lyon Street Capital, an estimated $18.9M sold.

Based on aggregated 13F filings for Q2 2017.